{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:07Z","timestamp":1707525187555},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,9]]},"DOI":"10.7759\/cureus.43246","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T06:03:56Z","timestamp":1691647436000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Immune-Mediated Colitis Induced by Checkpoint Inhibitors in an Adolescent With Lynch Syndrome"],"prefix":"10.7759","author":[{"given":"Rachel V","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt A","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifat","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory E","family":"Idos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trilokesh","family":"Kidambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Lynch syndrome","author":"Bhattacharya P","year":"2023","unstructured":"Bhattacharya P, McHugh TW. Lynch syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.01.014","article-title":"Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: systematic review and meta-analysis","volume":"24","author":"Abu-Ghazaleh N","year":"2022","unstructured":"Abu-Ghazaleh N, Kaushik V, Gorelik A, Jenkins M, Macrae F. Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: systematic review and meta-analysis. Genet Med. 2022, 24:971-85. 10.1016\/j.gim.2022.01.014","journal-title":"Genet Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S278054","article-title":"An update on immune checkpoint therapy for the treatment of Lynch syndrome","volume":"14","author":"Therkildsen C","year":"2021","unstructured":"Therkildsen C, Jensen LH, Rasmussen M, Bernstein I. An update on immune checkpoint therapy for the treatment of Lynch syndrome. Clin Exp Gastroenterol. 2021, 14:181-97. 10.2147\/CEG.S278054","journal-title":"Clin Exp Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang L","year":"2021","unstructured":"Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol. 2021, 12:800879. 10.3389\/fimmu.2021.800879","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang DY","year":"2017","unstructured":"Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017, 6:e1344805. 10.1080\/2162402X.2017.1344805","journal-title":"Oncoimmunology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson JA","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022, 20:387-405. 10.6004\/jnccn.2022.0020","journal-title":"J Natl Compr Canc Netw"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17250","article-title":"Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis-authors' reply","volume":"57","author":"Dahl EK","year":"2023","unstructured":"Dahl EK, Abed OK, Kjeldsen J, et al.. Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis-authors' reply. Aliment Pharmacol Ther. 2023, 57:152-3. 10.1111\/apt.17250","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih H","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018, 6:95. 10.1186\/s40425-018-0411-1","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/171677-severe-immune-mediated-colitis-induced-by-checkpoint-inhibitors-in-an-adolescent-with-lynch-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:55Z","timestamp":1707508855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/171677-severe-immune-mediated-colitis-induced-by-checkpoint-inhibitors-in-an-adolescent-with-lynch-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.43246","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}